Search - tctmd.com

Displaying 81 - 100 of 105

Sort: Relevancy | Date

Presentation TCT 2016

TAVR 2016: Making the Case For New Patient Subsets (Low Risk, Bicuspid, etc.)

Presenter: Marian C. Hawkey, Patricia Keegan

October 30, 2016

News Opinion Editor's Corner TCT 2015

My Takeaways From TCT 2015

Shelley Wood

October 20, 2015

Presentation TCT 2015

TCT 79: Efficacy of Cangrelor in Lesions With High-Risk and Low-Risk Angiographic Characteristics The CHAMPION PHOENIX Trial

Presenter: Lisa K. Jennings, Neal S. Kleiman, Gregg W. Stone

October 13, 2015

News Conference News TCT 2015

Darbepoetin Plus Iron Fails to Reduce Transfusion Rates After TAVR in Anemia Patients

October 13, 2015

Presentation TCT 2015

The Case for TAVR Expansion to Lower-Risk Patients

Presenter: Martin B. Leon, Neil E. Moat, Nicolo Piazza

October 11, 2015

News Conference News TCT 2015

Symposia Highlights Variances Between Guideline-Based, ‘Real-World’ Indications for TAVR

October 11, 2015

News Conference News TCT 2015

Global TAVR Market Poised to Exceed DES Market by 2025

October 11, 2015

News Conference News TCT 2015

Asian TAVR Registry Shows Good Procedural and Clinical Results

October 11, 2015

News Conference News TCT 2014

Capture Devices Hold Promise for Decreasing TAVR-Related Stroke

September 15, 2014

News Conference News TCT 2014

TCT Course Director Outlines Current TAVR Controversies

September 14, 2014

News Conference News TCT 2014

Registry Data Show Promise of Valve-in-Valve TAVR in High-Risk Patients

September 14, 2014

News Conference News TCT 2014

Lively Debate on Use of TAVR for Lower-Risk Patients

September 14, 2014

Presentation TCT 2014

TAVR Is Preferred for All but the Lowest-Risk Patients!

Presenter: Alejandro O. Palacios, Ernesto M. Torresani, Alec S. Vahanian

September 13, 2014

Presentation TCT 2014

CON: A Call for Reason and Restraint!

Presenter: Michael J. Mack

September 13, 2014

Presentation TCT 2014

PRO: It has Already Happened and Is Justified!

Presenter: Nicolo Piazza

September 13, 2014

News Conference News TCT 2014

PARTNER Shows Clear TAVR Benefit at 5 Years in Inoperable Patients

Yael L. Maxwell

September 13, 2014

News Conference News TCT 2013

TAVR a Viable Option for Intermediate-Risk Patients

November 05, 2013

Presentation TCT 2013

Motion: The Envelope for TAVR Should be Expanded to All Candidates for Conventional AVR - For: The Data are Clear (And Common Sense Rules): TAVR is a Lower Risk Option than...

Presenter: Daniel Blackman

October 30, 2013

News Conference News TCT 2013

Two Trials to Assess TAVR in Moderate-Risk Patients

October 30, 2013

News Conference News TCT 2013

Long-Term Outcomes, Cost May Influence Use of TAVR in Moderate-Risk Patients

October 28, 2013

Advertisement

TAVR 2016: Making the Case For New Patient Subsets (Low Risk, Bicuspid, etc.)

My Takeaways From TCT 2015

TCT 79: Efficacy of Cangrelor in Lesions With High-Risk and Low-Risk Angiographic Characteristics The CHAMPION PHOENIX Trial

Darbepoetin Plus Iron Fails to Reduce Transfusion Rates After TAVR in Anemia Patients

The Case for TAVR Expansion to Lower-Risk Patients

Symposia Highlights Variances Between Guideline-Based, ‘Real-World’ Indications for TAVR

Global TAVR Market Poised to Exceed DES Market by 2025

Asian TAVR Registry Shows Good Procedural and Clinical Results

Capture Devices Hold Promise for Decreasing TAVR-Related Stroke

TCT Course Director Outlines Current TAVR Controversies

Registry Data Show Promise of Valve-in-Valve TAVR in High-Risk Patients

Lively Debate on Use of TAVR for Lower-Risk Patients

TAVR Is Preferred for All but the Lowest-Risk Patients!

CON: A Call for Reason and Restraint!

PRO: It has Already Happened and Is Justified!

PARTNER Shows Clear TAVR Benefit at 5 Years in Inoperable Patients

TAVR a Viable Option for Intermediate-Risk Patients

Motion: The Envelope for TAVR Should be Expanded to All Candidates for Conventional AVR - For: The Data are Clear (And Common Sense Rules): TAVR is a Lower Risk Option than...

Two Trials to Assess TAVR in Moderate-Risk Patients

Long-Term Outcomes, Cost May Influence Use of TAVR in Moderate-Risk Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content